The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection

Balistreri WF, Murray KF, Rosenthal P, Bansal S, Lin C-H, Kersey K, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66(2):371-378.

Publication Type:

Journal Article

Authors:

Balistreri, William F.; Murray, Karen F.; Rosenthal, Philip; Bansal, Sanjay; Lin, Chuan-Hao; Kersey, Kathryn; Massetto, Benedetta; Zhu, Yanni; Kanwar, Bittoo; German, Polina; Svarovskaia, Evguenia; Brainard, Diana M.; Wen, Jessica; Gonzalez-Peralta, Regino P.; Jonas, Maureen M.; Schwarz, Kathleen

Source:

Hepatology, Volume 66, Issue 2, p.371-378 (2017)

Cited On:

HCV in Children

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/27997679

Export Citation:

RIS Format

Top